Life Sciences

Gimv’s Life Sciences' mission is to invest in companies developing products that significantly benefit society.

Driven by the search for solutions to healthcare’s many unmet needs, Life Sciences focuses on companies developing treatments with clear potential for commercial differentiation. Gimv Life Sciences also operates in other life science areas such as medtech, digital health, industrial and agrobiotech. The team draws on Gimv’s 40-year track record as a pioneering life sciences investor with numerous success stories including Plant Genetic Systems, Ablynx, Breath Therapeutics, Covagen, Devgen, Prosensa and Prosonix.

Several of these success stories gradually also found their way to the stock exchange. With strong complementary scientific and business backgrounds, we actively support life science companies from early preclinical proof-of-concept to clinical success. Along with like-minded entrepreneurs and scientists, we are committed to addressing unmet clinical needs.

Why Gimv Life Sciences?

Solid therapeutics investment experience as well as in other life sciences domains
International and entrepreneurial mindset, working with founders and management team to make their company a success
Working in an evergreen setting, offering great flexibility in terms of deal structures and investment timelines
Investing in clear unmet (medical) needs, combining financial with societal return

Investment focus

Companies involved in drug development, from early preclinical to late clinical stages
Opportunities in other life science areas such as medtech, digital health, industrial and agrobiotech

Kinaset Therapeutics

Improving the life of asthma patients! Improving the life of asthma patients! Improving the life of asthma patients!

Improving the life of asthma patients!

Kinaset Therapeutics was founded in 2020 through a Series A round by Gimv, 5 AM Ventures and Atlas Ventures. The company is developing a new, innovative and best-in-class treatment for patients with respiratory diseases, with a primary focus on severe asthma. Asthma affects more than 300 million patients worldwide, with about 10% of cases being severe asthma. These patients face various problems such as frequent exacerbations, decreased lung function and reduced quality of life. Gimv’s investment allowed Kinaset to perform a first clinical study, proven its drug is safe and efficacious.